Ovarian Cancer

Latest News
May 16th 2025

Access to Minimally Invasive Surgery for Advanced Ovarian Cancer Varies Widely by Facility

May 13th 2025

Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer

May 11th 2025

Global Analysis Sheds Light on Women’s Cancer Trends

May 9th 2025

FDA Approves First Treatment for KRAS-Mutated Recurrent LGSOC

April 27th 2025

No Definitive Link Found Between Female Infertility and Gynecological Cancer

Ovarian Cancer Guideline Updates 2024

Ronald D. Alvarez, MD, MBA, analyzes recent changes to NCCN guidelines for ovarian cancer care and provides updates on the latest clinical trial data.

Ronald D. Alvarez, MD, MBA, analyzes recent changes to NCCN guidelines for ovarian cancer care and provides updates on the latest clinical trial data.
Video Interviews
View All
May 20th 2025

The Use of PARP Inhibitors in Ovarian Cancer

May 20th 2025

Earlier Introduction of Antibody-Drug Conjugates

May 13th 2025

The Role of Novel Targeted Therapies

May 13th 2025

Antibody-Drug Conjugates for Platinum-Resistant Ovarian Cancer

May 12th 2025

Improving Clinician Awareness and Adoption of Molecular Testing

May 12th 2025

The Impact of Tumor Heterogeneity in Ovarian Cancer

May 5th 2025

Comprehensive Molecular Testing in Patients With Ovarian Cancer

May 5th 2025

Emerging Molecular Biomarkers in Ovarian Cancer

April 28th 2025

FRα Biomarker Testing in Patients With Ovarian Cancer

April 28th 2025

The Role of Guidelines on Molecular Testing in Ovarian Cancer

More News

BMI graphic | Image Credit: Vitalii Vodolazskyi - stock.adobe.com
April 22nd 2025

Overweight-to-Obese Trajectory in Adulthood May Raise Ovarian Cancer Risk

Brooke McCormick
Individuals who transition from overweight to obese during adulthood may face a higher ovarian cancer risk, highlighting the importance of tracking body fat changes.
CA-125 test | Image Credit: jarun011 - stock.adobe.com
April 17th 2025

Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays

Brooke McCormick
Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.
Patient taking survey | Image Credit: terovesalainen - stock.adobe.com
April 15th 2025

EHR-Based Symptom Inventory Shows Potential for Ovarian Cancer Monitoring

Brooke McCormick
The electronic health record (EHR)–based symptom inventory identified symptom prevalence and associated comorbidities, but no ovarian cancers were diagnosed during the study period.
Ovarian cancer animation | Image Credit: Dr_Microbe - stock.adobe.com
April 9th 2025

Sociodemographic Factors Impact Cytoreductive Surgery Decisions in Advanced Ovarian Cancer

Brooke McCormick
Patients with advanced epithelial ovarian cancer who were non-Hispanic Black, older, had lower household income, resided in nonmetropolitan areas, and were unmarried had higher odds of refusing cytoreductive surgery.
Woman stepping on scale | Image Credit: Hunterframe - stock.adobe.com
April 3rd 2025

Obesity May Increase Surgical Complications in Epithelial Ovarian Cancer

Brooke McCormick
The most common surgical complications in obese patients with epithelial ovarian cancer (EOC) include wound infection, intestinal problems, and a higher 30-day readmission rate.
Woman affected by blurry vision | Image Credit: Prostock-studio - stock.adobe.com
March 25th 2025

Ocular Adverse Events From Mirvetuximab Soravtansine Not Associated With HRQoL Impact in FRα+ Ovarian Cancer

Brooke McCormick
New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) for patients with folate receptor alpha-positive (FRα+), platinum-resistant ovarian cancer.
Dr Toon Van Gorp
March 20th 2025

Dr Toon Van Gorp: Mirvetuximab Soravtansine Should Be Global Standard for FRα+ Ovarian Cancer

Brooke McCormick Toon Van Gorp, MD, PhD
Toon Van Gorp, MD, PhD, a MIRASOL trial investigator, emphasizes that the final analysis reinforces the efficacy of mirvetuximab soravtansine-gynx (Elahere; AbbVie) in patients with folate receptor alpha-positive (FRα+), platinum-resistant ovarian cancer.
Dr Toon Van Gorp
March 18th 2025

Final MIRASOL Trial Analysis Confirms Consistent Efficacy of Mirvetuximab Soravtansine

Brooke McCormick Toon Van Gorp, MD, PhD
The final analysis showed similar overall survival, progression-free survival, and objective response rates, with no new safety signals identified compared with the primary analysis.
Ovarian cancer awareness | Image Credit: Queenmoonlite Studio - stock.adobe.com
March 17th 2025

Updated MIRASOL Data Confirm Efficacy of Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Ovarian Cancer

Brooke McCormick
The final data analysis confirmed that mirvetuximab soravtansine-gynx (Elahere; AbbVie) significantly improves progression-free survival, overall survival, and objective response in patients with folate receptor alpha-positive (FRα+) platinum-resistant ovarian cancer.
Dr Chun Chao
March 6th 2025

Navigating Future Public Health Emergencies With Pandemic Lessons on Ovarian Cancer

Brooke McCormick Chun Chao, PhD, MS
Optimizing telehealth during public health emergencies to minimize in-person appointments puts less burden on patients and may lead to better outcomes, according to Chun Chao, PhD, MS, of Kaiser Permanente Southern California.
Dr Chun Chao
March 3rd 2025

Stable Remission Rates Found in Insured Patients With Ovarian Cancer Amid COVID-19 Pandemic

Brooke McCormick Chun Chao, PhD, MS
These findings may not be generalizable to uninsured patients with ovarian cancer, who face unique barriers to care compared with insured patients.
Dr Chun Chao
February 27th 2025

Diving into the COVID-19 Pandemic’s Impact on Ovarian Cancer, Remission Rates

Brooke McCormick Chun Chao, PhD, MS
With the potential for future pandemics, Chun Chao, PhD, MS, emphasizes the importance of learning from the COVID-19 pandemic's impact on cancer care, particularly for patients with ovarian cancer.
COVID-19 pandemic illustration | Image Credit: James Thew - stock.adobe.com
February 20th 2025

Ovarian Cancer Remission Rates Remained Stable Before, After COVID-19 Pandemic

Brooke McCormick
The comparable rates of remission pre- and post-pandemic suggest that COVID-19 did not negatively impact the outcomes of patients with ovarian cancer.
Female patient drinking water and eating healthy | Image Credit: Viacheslav Yakobchuk - stock.adobe.com
February 18th 2025

Ovarian Cancer Outcomes Linked to Preoperative Immunonutritional Status

Brooke McCormick
In patients with early-stage ovarian cancer, a high prognostic nutritional index improved survival, while a high systemic immune-inflammation index worsened it. In advanced stages, both affected overall survival but not progression-free survival.
Ovarian cancer illustration | Image Credit: tashatuvango - stock.adobe.com
February 12th 2025

High Prevalence of Sarcopenia Identified in Patients With Ovarian, Endometrial Cancer

Brooke McCormick
The high prevalence of sarcopenia in patients with ovarian and endometrial cancers underscores the importance of early screening and preventive measures for these populations.
Genetic testing illustration | Image Credit: Giovanni Cancemi - stock.adobe.com
February 5th 2025

Physician Gaps in Genetic Testing Knowledge May Impact Ovarian Cancer Care

Brooke McCormick
While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient access to genetic counseling.
Ovarian cancer awareness illustration | Image Credit: Queenmoonlite Studio - stock.adobe.com
February 3rd 2025

Olaparib Leads PARP Inhibitors in Boosting OS for Platinum-Sensitive Recurrent Ovarian Cancer

Brooke McCormick
While all poly ADP-ribose polymerase (PARP) inhibitors improved progression-free survival, olaparib significantly extended overall survival (OS), making it a preferred option.
Clinician holding box of niraparib | Image Credit: luchschenF - stock.adobe.com
January 28th 2025

Niraparib Extends PFS, Time to Next Treatment in Patients With EOC, Especially BRCA-Mutated Cases

Brooke McCormick
First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment (rwTTNT) in patients with epithelial ovarian cancer (EOC), with the greatest benefit observed in those considered homologous recombination-deficient (HRd) and those with BRCA-mutated (BRCAm) tumors.
Ovarian cancer awareness illustration | Image Credit: Queenmoonlite Studio - stock.adobe.com
January 23rd 2025

Real-World Study Highlights PARP Inhibitor Challenges in Ovarian Cancer Care

Brooke McCormick
Nearly half of patients with advanced ovarian cancer treated with first-line poly-ADP-ribose polymerase (PARP) inhibitors experienced recurrence in this real-world study, emphasizing the need for enhanced strategies to optimize postrecurrence treatment.
Surgeon team performing an operation | Image Credit: Georgii - stock.adobe.com
January 21st 2025

Gynecologic Oncology Practices Evolve With Surgical De-Escalation Trends

Brooke McCormick
Researchers identified a 15-year shift toward surgical de-escalation in gynecologic oncology, marked by fewer surgical interventions, increased adoption of minimally invasive techniques, and a greater focus on fertility preservation and sentinel lymph node procedures.
AI illustration | Image Credit: putilov_denis - stock.adobe.com
January 19th 2025

AI Outperforms Traditional Methods in Predicting Ovarian Cancer Surgery Outcomes

Brooke McCormick
Artificial intelligence (AI) models, particularly artificial neural networks and machine learning, outperform traditional methods in predicting post–complete cytoreduction outcomes in patients with ovarian cancer, including overall survival, no residual disease, and postoperative complications.
Ovarian cancer animation | Image Credit: MohammedElAmine - stock.adobe.com
January 16th 2025

High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer

Brooke McCormick
High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Physician holding niraparib box | Image Credit: luchschenF - stock.adobe.com
January 14th 2025

Niraparib Improves Outcomes in Patients With Stage III EOC, No Visible Residual Disease

Brooke McCormick
Patients with stage III epithelial ovarian cancer (EOC) and no visible residual disease after primary cytoreductive surgery had significantly longer real-world progression-free survival and time to next treatment when treated with first-line maintenance niraparib compared with those with higher-risk disease.
Ovarian cancer animation | Image Credit: Dr_Microbe - stock.adobe.com
January 9th 2025

Nomogram Predicts Overall Survival in Patients With Ovarian Cancer, Liver Metastases

Brooke McCormick
Researchers developed and validated a nomogram to predict 1-, 2-, and 3-year overall survival (OS) in patients with ovarian cancer and liver metastases (OCLM), outperforming an external model in stability and accuracy.
Image depicting the global population | Image Credit: flashmovie - stock.adobe.com
January 7th 2025

Global Trends in Ovarian Cancer Incidence Highlight Regional, Histological Variations

Brooke McCormick
Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, influenced by genetic, reproductive, and socioeconomic factors.
TOP 5 ovarian cancer articles of 2024 | Image Credit: Venngage
December 29th 2024

Top 5 Most-Read Ovarian Cancer Content of 2024

Brooke McCormick
The top 5 ovarian cancer articles of 2024 covered topics such as the impact of air pollution on ovarian cancer risk, treatment strategies for patients with liver metastases, and the benefits of early diagnosis through symptom-triggered testing.
Healthy lifestyle illustration | Image Credit: SkyLine - stock.adobe.com
December 23rd 2024

Exercise May Benefit Chemotherapy-Induced Peripheral Neuropathy in Patients With Ovarian Cancer

Brooke McCormick
Exercise interventions may help manage chemotherapy-induced peripheral neuropathy (CIPN) in patients with ovarian cancer through improved physical activity and muscle function, but evidence remains limited.
Dr Alice Lee
December 16th 2024

Addressing Ovarian Cancer Outcome Disparities With Cultural Understanding, Disaggregated Research

Brooke McCormick
In the final part of our interview, Alice W. Lee, PhD, MPH, highlights the importance of addressing ovarian cancer care disparities and beyond by understanding cultural and behavioral factors and adopting a more disaggregated approach to research.
Dr Alice Lee
December 13th 2024

Uncovering Factors Driving Survival in Hawaiian/Pacific Islander, Asian Indian/Pakistani Patients With Ovarian Cancer

Brooke McCormick
In part 2 of our interview, Alice W. Lee, PhD, MPH, of California State University, Fullerton, examines survival disparities between Hawaiian/Pacific Islander and Asian Indian/Pakistani patients with ovarian cancer and suggests areas for further research.
Dr Alice Lee
December 11th 2024

Revealing Ovarian Cancer Survival Gaps Among Asian American Subgroups

Brooke McCormick
Alice W. Lee, PhD, MPH, of California State University, Fullerton, discusses her study on ovarian cancer survival disparities among disaggregated Asian American subgroups, emphasizing the need for a subgroup-specific approach in cancer research.
123456>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo